Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.

Stephanie L SamuelsAnastasia ChajeckiPamela HuMichelle KayserKate WeymanBernard PanElizabeth A BrownMichelle Van NameRisa M Wolf

Published in: Diabetes, obesity & metabolism (2024)

Real-world use of GLP-1RAs in youth with T2D is associated with decreased HbA1c levels, despite challenges with access and adherence. GLP-1RA treatment may reduce insulin doses for youth with T2D.

Keyphrases

mental health
physical activity
young adults
type diabetes
rheumatoid arthritis
glycemic control
metabolic syndrome
disease activity
combination therapy
weight loss